-
The Coronavirus Impacts Cancer Clinical TrialsThe National Cancer Institute and the Food and Drug Administration have provided guidance for managing clinical trials amid the spread of the novel coronavirus. Cancer centers are making changes to care for some patients enrolled in trials.
by Anna Azvolinsky
-
New Drugs for an Elusive Cancer TargetMedical oncologist and lung cancer expert Roy S. Herbst discusses early data on drugs that target a mutated form of the KRAS protein.
by Anna Azvolinsky
-
Clinical Trials: An African American Survivor’s ExperienceMelvin Mann benefited from joining a pivotal clinical trial for chronic myelogenous leukemia, but participation came with logistical challenges.
by Melvin Mann
-
A Switch From Intravenous to Oral Chemo?Compared with intravenous paclitaxel, the oral form of the chemotherapy drug was associated with improved tumor shrinkage in metastatic breast cancer patients.
by Ashley P. Taylor
-
Possible New Treatments for Patients With Metastatic HER2-Positive Breast CancerStudies presented at the San Antonio Breast Cancer Symposium show additional treatment options.
by Marci A. Landsmann
-
Treating Fear of RecurrenceCognitive behavioral therapy may help cancer survivors cope with fear of recurrence, some studies say.
by Jon Kelvey
-
Misunderstandings About Cancer DNA TestsMany cancer patients who received genomic testing of their cancers in a clinical trial did not fully understand the purpose of the testing.
by Emma Yasinski
-
HIV Can Worsen Cancer Treatment OutcomesPeople with HIV who develop certain cancers are more likely to die from them than patients without HIV—even if they receive similar treatment.
by Jon Kelvey
-
Helping Cancer Survivors SleepA clinical trial comparing acupuncture and cognitive behavioral therapy found that they are both helpful for people who are experiencing sleep problems after cancer treatment.
by Cheryl Platzman Weinstock
-
So You Want to Serve on a Scientific Review Panel?Cancer patient advocates who review research proposals can provide valuable perspective.
by Bob Riter, Monica Vakiner and Carole Baas
Scientists present data on the risks of immune checkpoint inhibitors so more patients can tap into the treatment.
by Marci A. Landsmann
Tissue and Liquid Biopsy for Targeted TherapyTailored treatments led to better outcomes than standard of care when biomarker results from liquid biopsy and tumor tissue aligned.
by Eric Fitzsimmons
Cancer Vaccines Show Promise in Early TrialsWhile mRNA vaccines offer a personalized approach to triggering an immune response, peptide vaccines could be a one-size-fits-all treatment. Researchers are exploring both options.
by Thomas Celona
Declining Breast Cancer Mortality in Younger WomenU.S. breast cancer deaths declined for women ages 20 to 49, which researchers credit to wider screening and better treatment.
by Kevin McLaughlin
-
Inaugural AACR IO Conference Kicks Off With Celebration of Immune CheckpointsImmune checkpoint icons James Allison and Arlene Sharpe shared their journeys and a look ahead on the opening night of the inaugural AACR IO conference.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
